Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib + Gefitinib in Metastatic Renal Cell Carcinoma
NCT00113529Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2004
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by Pfizer. Primary endpoint: Overall Confirmed Objective Disease Response. Started Oct 2004; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00113529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113529.